

Acne Medications:	Renin Inhibitors 17	Miscellaneous
Oral 3		Elaprase® (Hunter's Syndrome Injectable) 28
Topical-Anti-infectives 4		Soliris® (Paroxysmal Nocturnal Hemoglobinuria Injectable) 28
Topical-Retinoids 5		
Topical-Rosacea 5		
Alzheimer's Medications:	Anti-infectives:	Mood Stabilizers 28
Cholinesterase Inhibitors/NMDA	Cephalosporins: 1st Generation 17	
Receptor Antagonists 5	Cephalosporins: 2nd Generation 17	
Analgesics:	Cephalosporins: 3rd Generation 17	
COX-2 Inhibitors 6	Ketolides 17	
Narcotics-Short Acting 6-7	Macrolides 18	
Narcotics-Long Acting 7	Oxazolidinones 18	
NSAIDS 8	Penicillins (Oral) 18	
Anemia Medications:	Quinolones 18	
Hematopoietic/Erythropoietic Agents 8	Onychomycosis Agents 19	
Ankylosing Spondylitis Injectables 8	Anti-virals: Herpes 19	
Anti-anxiety:	Genital Antivirals 19	
Anxiolytics 8	Influenza Medications 19	
Anticoagulants 9	Influenza Vaccines 19	
Anticonvulsants 9	Miscellaneous 19	
Anti-depressants:	Topical Antibiotics 20	
Novel 10	Anti-migraine:	
SSRIs 10	Triptans 20	
Tricyclics 11	Anti-obesity 20	
MAO Inhibitors 11	Anti-psychotic:	
Anti-diabetics:	Atypicals & Combinations 21	
Alpha Glucosidase Inhibitors 11	Typicals 21	
Biguanides & Combinations 11	Botulinum Toxins 21	
Peptide Hormones 11	BPH:	
Insulin (Injectable and Inhaled) 12	Alpha Blockers 22	
Oral-Meglitinides 12	Androgen Hormone Inhibitors 22	
Sulfonylureas 2nd Generation 12	Cardiac Glycosides 22	
Thiazolidinediones & Combinations 13	Chemical Dependency 22	
Dipeptidyl Peptidase Inhibitors 13	Constipation: Chronic 22	
Anti-emetics:	Cough and Cold Preparations 23	
NK1/5HT3 Antagonists 13	Coronary Vasodilators/Antianginals:	
Other 13	Oral 23	
Anti-hyperkinesis and Anti-Narcolepsy:	Topical 23	
Short/Intermediate-Acting MPH 14	Gastrointestinals:	
Long-Acting MPH 14	Crohn's Disease Injectables 23	
Short/Intermed-Acting Amphetamines 14	H2-blockers 23	
Long-Acting Amphetamines 14	Proton Pump Inhibitors 24	
Non-Stimulants Products 14	Ulcerative Colitis Injectables 24	
Xyrem 14	Glucocorticoids:	
Anti-hypertensives:	Topical 25	
ACE Inhibitors 14	Growth Stimulating Agents 26	
ACEI with Hydrochlorothiazide 15	Hepatitis C Agents 26	
ACE Inhibitors with CCBs 15	Immunomodulators: Topical 26	
Angiotensin Receptor Blockers 15	Lipotropics:	
ARBs/Hydrochlorothiazide Combos 15	Bile Acid Sequestrants 26	
ARBs/CCB Combos 15	Fibric Acid Derivatives 27	
Beta-Blockers 16	Niacin Derivatives 27	
Calcium Channel Blockers 16	Statins 27	
	Miscellaneous/Combinations 27	

Phone Numbers for Vermont Medicaid PBM Program

MedMetrics Health Partners (MHP)**Clinical Call Center:****PA Requests**

Tel: 1-800-918-7549; Fax: 1-866-767-2649

Note: Fax requests are responded to within 24 hrs.

For urgent requests, please call MHP directly.

MHP Program Rep-Vermont:*Assistance with any issues related to the PBM program.*

Nancy Miner, CPhT, (o) 802-879-5638

(f): 802-879-5919

E-mail: nancy_miner@medmetricshsp.com

MHP Clinical Staff:

Diane Neal, RPh (o): 802-879-5605

(f): 802-879-5919

E-mail: diane_neal@medmetricshsp.com

OVHA Medical Staff:*Medical Director*

Erin Reisfeld, M.D., (o) 802-879-5920;

(f) 802-879-5963

OVHA Pharmacy Unit Staff:

Stacey Baker, (o) 802-879-5912;

(f) 802-879-5919

E-mail: Stacey.Baker@ahs.state.vt.us

ACNE DRUGS: ORAL

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

DOXYCYCLINE† 20 mg, 50 mg, 75 mg, 100 mg tab, cap

ERY-TAB® (erythromycin base, delayed release)

ERYTHROCIN† (erythromycin stearate)

ERYTHROMYCIN BASE†

ERYTHROMYCIN ESTOLATE†

ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S.®,
Eryped®)

ERYTHROMYCIN STEARATE†

MINOCYCLINE† 50 mg, 75 mg, 100 mg

TETRACYCLINE† 250 mg, 500 mg cap

SUMYCIN† 250 mg, 500 mg cap

ISOTRETINOIN† 10 mg, 20 mg, 40 mg cap (SOTRET,
CLARAVIS, AMNESTEEM)

PA REQUIRED

Adoxa®* (doxycycline monohydrate) 50 mg, 75 mg tab, 100 mg tab, 150 mg tab

Adoxa Pak®* (doxycycline monohydrate) 1/75 mg, 1/100 mg, 1/150 mg, 2/100 mg

Doryx®* (doxycycline hyclate) 75 mg, 100 mg cap
doxycycline monohydrate pak† (compare to Adoxa Pak®) 1/75 mg, 1/100 mg, 1/150 mg, 2/100 mg

Monodox®* (doxycycline monohydrate) 50 mg, 100 mg cap

Oracea® (doxycycline monohydrate) 40 mg cap

Periostat®* (doxycycline hyclate) 20 mg, 100 mg tab

Vibramycin®* (doxycycline hyclate) 50 mg, 100 mg cap

Vibramycin® (doxycycline hyclate) suspension

Vibratab®* (doxycycline hyclate) 100 mg tab

All other brands

E.E.S.®* (erythromycin ethylsuccinate)

Eryc®* (erythromycin base, delayed release)

Eryped® (erythromycin ethylsuccinate)

PCE Dispertab® (erythromycin base)

All other brands

Minocin®* (minocycline) 50 mg, 75 mg, 100 mg cap

Dynacin®* (minocycline) 50 mg, 75 mg, 100 mg cap/tab

Solodyn® (minocycline) 45 mg, 90 mg, 135 mg tabs

All other brands

Sumycin® (tetracycline) 250 mg, 500 mg tab

Sumycin® (tetracycline) 125 mg/5ml syrup

All other brands

Accutane®* (isotretinoin) 10 mg, 20 mg, 40 mg caps

All other brands

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ACNE DRUGS: TOPICAL ANTI-INFECTIVES

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

BENZOYL PEROXIDE PRODUCTS

BENZOYL PEROXIDE 2.5%, 5%, 10% G, L, W; 10% C; 3%, 5%, 6%, 8%, 9%, 10% L; 3%, 6%, 9% P †

CLINDAMYCIN PRODUCTS

CLINDAMYCIN 1% S, G, L, P †

ERYTHROMYCIN PRODUCTS

ERYTHROMYCIN 2% S, G, P †

SODIUM SULFACETAMIDE PRODUCTS

SODIUM SULFACETAMIDE 10% L†

COMBINATION PRODUCTS

ERYTHROMYCIN / BENZOYL PEROXIDE†

SODIUM SULFACETAMIDE / SULFUR L†

OTHER

PA REQUIRED

Benzac AC® 2.5%, 5%, 10% G, W
 Benzashave® 5%, 10% C
 Brevoxyl® 4%, 8% W; 4% G; 4%, 8% L
 Clinac BPO® 7% G
 Desquam-E/X® 2.5%, 5%, 10% G; 5%, 10% W
 Inova 4% P
 Panoxyl/AQ 2.5%, 5%, 10% G; 5%, 10% B
 Triaz® 3%, 6%, 9% G; 3%, 6%, 9% P
 Zaclair® 4%, 8% L
 All other brands

Cleocin-T®* (clindamycin 2% G)
 Evoclin® (clindamycin 2% F)
 Clindagel® (clindamycin 1% G)
 All other brands

Akne-Mycin® (erythromycin 2% O)
 Erygel®* (erythromycin 2% G)
 All other brands

Klaron®* (sodium sulfacetamide 10% L)
 All other brands

Benzaclin®, DUAC® (clindamycin/benzoyl peroxide)
 Benzamycin®* (erythromycin/benzoyl peroxide)
 Sulfoxy (erythromycin/benzoyl peroxide)
 Z-Clinz® (clindamycin/benzoyl peroxide kit)
 All other brands

Avar® (sodium sulfacetamide/sulfur G)
 Sulfacet-R®* (sodium sulfacetamide/sulfur L)
 Plexion® (sulfacetamide/sulfur S)
 All other brands

Azelex® (azelaic acid 20% C)
 All other brands any topical acne anti-infective medication

C=cream, E=emulsion, F=foam, G=gel, L=lotion, O=ointment, P=pads, S=solution, W=wash, B=bar

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ACNE DRUGS: TOPICAL - RETINOID

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

TRETINOIN† (specific criteria required for ages <10 or >34) 0.025%, 0.05%, 0.1% C; 0.01%, 0.025% G

TAZORAC® (azarotene) 0.05%, 0.1% C, G

PA REQUIRED

All brand tretinoin products (Avita®, Retin-A®, Retin-A Micro® 0.1%, 0.04%, Tretin-X® etc.)

Differin® (adapalene) 0.1% C, G; 0.3% G

Avage® (azarotene) ♣

Renova® (tretinoin) ♣

Solage® (tretinoin/mequinol) ♣

Tri-Luma® (tretinoin/hydroquinone/fluocinolone) ♣

♣ Not indicated for acne. Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.).

C=cream, G=gel

ACNE DRUGS: TOPICAL - ROSACEA

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

METRONIDAZOLE† 0.75% C, G, L

C=cream, G=gel, L=lotion

PA REQUIRED

All brand metronidazole products (MetroCream® 0.75% C, MetroGel® 0.75% G, MetroGel® 1% G, MetroLotion® 0.75% L, Noritate® 1% C, Rozex® 0.75% G etc.)

Finacea® (azelaic acid) 15% G

ALZHEIMER'S MEDICATIONS: CHOLINESTERASE INHIBITORS/NMDA RECEPTOR ANTAGONISTS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

CHOLINESTERASE INHIBITORS

ARICEPT® (donepezil) Tablet (QL = 1 tablet/day)

EXELON® (rivastigmine) Capsule (QL = 2 capsules/day)

ARICEPT® ODT (donepezil) (QL = 1 tablet/day)

EXELON® (rivastigmine) Oral Solution

EXELON® (rivastigmine transdermal) Patch (QL = 1 patch/day)

NMDA RECEPTOR ANTAGONIST

NAMENDA® (memantine) Tablet

NAMENDA® (memantine) Oral Solution

PA REQUIRED

Cognex® (tacrine) Capsule §

Razadyne® (galantamine) Tablet §

Razadyne ER® (galantamine) Capsule §

Razadyne® (galantamine) Oral Solution §

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANALGESICS: COX-2 INHIBITORS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

CELEBREX® (celecoxib) (age ≥ 60 yrs) (*QL = 2 capsules/day*)

PA REQUIRED

Celebrex® (age < 60 yrs) (*QL = 2 capsules/day*)

ANALGESICS: NARCOTICS-SHORT ACTING

LENGTH OF AUTHORIZATION: 3 MONTHS, SUBSEQUENT APPROVAL UP TO 6 MONTHS

QUANTITY LIMITS APPLY

NO PA REQUIRED

ACETAMINOPHEN W/CODEINE† (compare to Tylenol® w/codeine)
 ACETAMINOPHEN W/HYDROCODONE† (compare to Vicodin®, Loracet®, Maxidone®, Norco®, Zydome®)
(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)
 ACETAMINOPHEN W/OXYCODONE† (compare to Percocet®)
(QL 10/650 = 6 tablets/day)
 ACETAMINOPHEN W/PROPOXYPHENE† (compare to Darvocet-N®)
(QL 100/650 = 6 tablets/day)
 ASPIRIN W/CODEINE†
 ASPIRIN W/OXYCODONE† (compare to Percodan®)
 BUTALBITAL COMP. W/CODEINE† (compare to Fiorinal® w/codeine)
 CODEINE SULFATE†
 DIHYDROCODEINE COMPOUND† (compare to Synalgos-DC®)
 HYDROCODONE† (plain, w/acetaminophen, or w/ibuprofen)
 HYDROMORPHONE† (compare to Dilaudid®)
 MEPERIDINE† (compare to Demerol®) (30 tabs or 5 day supply)
 MORPHINE SULFATE†
 MORPHINE SULFATE† (compare to Roxanol®)
 OXYCODONE† (plain, w/acetaminophen or w/ibuprofen)
 PENTAZOCINE† (compare to Talwin®)
 PROPOXYPHENE† (compare to Darvon®)
 PROPOXYPHENE COMPOUND.† (compare to Darvon Compound®)
 PROPOXYPHENE N W/ ACETAMINOPHEN†
 ROXICET® (oxycodone w/ acetaminophen)
 ROXICODONE INTENSOL® (oxycodone w/ acetaminophen)
 ROXICODONE® (oxycodone HCL)
 TRAMADOL† (compare to Ultram®)
 TRAMADOL/APAP† (compare to Ultracet®)

PA REQUIRED

Acetaminophen w/ codeine: *all branded products*
 Acetaminophen w/ hydrocodone: *all branded products*
(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)
 Acetaminophen w/ oxycodone: *all branded products*
(QL 10/650 = 6 tablets/day)
 Actiq® (fentanyl lozenge on a stick: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg)
 Anexia®*
 Bancap HC®
 Butorphanol Nasal Spray (*QL = 2 units/month*)
 Capital® w/Codeine*
 Combunox®
 Darvocet-N®* (*QL 100/650 = 6 tablets/day*)
 Darvon Compound®*
 Darvon®*
 Darvon-N®*
 Demerol*
 Dilaudid®*
 Endocet®
 Endodan®
 fentanyl citrate† transmucosal (compare to Actiq®)
 Fentora® (fentanyl citrate buccal tablets)
 Fioricet w/codeine®*
 Liquicet®* (hydrocodone w/acetaminophen)
 Lorcet®* (also HD, PLUS)
 Lortab®*
 Magnacet®
 Maxidone®
 Meperidine (*Qty > 30 tabs or 5 day supply*)
 Nalbuphine
 Norco®*
 Nubain®*
 Numorphan®
 Opana®
 Oxyfast®*
 OxyIR®*
 Panlor DC®*
 Pentazocine and Naloxone
 Percocet®*

continued on next page

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

continued from previous page

Percodan®*
Propoxyphene: *all branded products**
Roxanol®*
Synalgos DC®*
Talacen®*
Talwin®* and brand combinations
Talwin NX®*
Tylenol® #3*
Tylenol® #4*
Tylox®*
Ultracet®
Ultram®*
Ultram ER®
Vicodin®*
Vicoprofen®*
Wygesic®*
Xodol®
Zydone®*

ANALGESICS: NARCOTICS-LONG ACTING

**LENGTH OF AUTHORIZATION: INITIAL APPROVAL 3 MONTHS, SUBSEQUENT APPROVAL UP TO 6 MONTHS
QUANTITY LIMITS APPLY**

THERAPY SPECIFIC PA FAX FORM FOR LONG ACTING NARCOTICS AVAILABLE ON OVHA WEB-SITE.

NO PA REQUIRED

FENTANYL PATCH† (compare to Duragesic) 25 mcg/hr, 50 mcg/hr,
(QL=15 patches/30 days)

FENTANYL PATCH† (compare to Duragesic) 75 mcg/hr, 100 mcg/hr,
(QL=30 patches/30 days)

METHADONE† (compare to Dolophine) 5 mg, 10 mg

MORPHINE SULFATE ER† (compare to MS Contin®)
(QL=90 tablets/strength/30 days)

PA REQUIRED

Avinza® (morphine sulfate XR) (QL= 30 capsules/strength/30 days)
Dolophine®*
Duragesic-12® 12.5 mcg/hr (QL=15 patches/30 days)
Duragesic®* 25 mcg/hr, 50 mcg/hr, (QL=15 patches/30 days)
Duragesic®* 75 mcg/hr, 100 mcg/hr (QL= 30 patches/30 days)
Fentanyl Patch† (compare to Duragesic) 12.5 mcg/hr (QL=15 patches/30 days)
Kadian® (morphine sulfate XR) (QL= 60 capsules/strength/30 days)
Methadone 40 mg Dispersible Tablets §
MS Contin®* (QL=90 tablets/strength/30 days)
Opana ER® (QL=60 tablets/strength/30 days)
Oramorph SR®* (QL=90 tablets/strength/30 days)
Oxycodone ER† (QL=90 tablets/strength/30 days)
OxyContin® (QL= 90 tablets/strength/30 days)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANALGESICS: NSAIDS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

NO PA REQUIRED

DICLOFENAC POTASSIUM† (compare to Cataflam®)
 DICLOFENAC SODIUM† (compare to Voltaren®)
 DIFLUNISAL† (compare to Dolobid®)
 ETODOLAC†
 FENOPROFEN† (compare to Nalfon®)
 FLURBIPROFEN† (compare to Ansaid®)
 IBUPROFEN† (compare to Motrin®)
 INDOMETHACIN†(compare to Indocin®)
 KETOPROFEN†
 KETOPROFEN ER†
 MECLOFENAMATE SODIUM† (compare to Meclomen®)
 NABUMETONE†
 NAPROXEN† (compare to Naprosyn®)
 NAPROXEN SODIUM† (compare to Anprox®, Naprelan®)
 OXaprozin† (compare to Daypro®)
 PIROXICAM† (compare to Feldene®)
 SULINDAC† (compare to Clinoril®)
 TOLMETIN SODIUM†

PA REQUIRED

Anaprox®*
 Anaprox DS®*
 Ansaid®*
 Arthrotec®
 Cataflam®*
 Clinoril®*
 Daypro®*
 Dolobid®*
 EC-Naprosyn® *
 Feldene®*
 Indocin®*
 Indocin SR®
 Ketorolac† *QL = 20 doses post PA approval*
 Meloxicam† (compare to Mobic®)
 Mefanamic acid† (compare to Ponstel®)
 Mobic®
 Motrin®*
 Nalfon®*

ANEMIA: HEMATOPOIETIC/ERYTHROPOIETIC AGENTS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

ARANESP® (darbepoetin alfa)
 PROCRIT® (epoetin alpha)

PA REQUIRED

EpoGen® (epoetin alpha)

ANKYLOSING SPONDYLITIS: INJECTABLES

LENGTH OF AUTHORIZATION: INITIAL PA 3 MONTHS; 12 MONTHS THEREAFTER

THERAPY-SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ENBREL® (etanercept)
 HUMIRA® (adalimumab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Remicade® (infliximab)

ANTI-ANXIETY: ANXIOLYTICS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

ALPRAZOLAM† (compare to Xanax®)
 ALPRAZOLAM XR† (compare to Xanax XR®)
 BUSPIRONE† (compare to Buspar®)
 CHLORDIAZEPOXIDE† (compare to Librium®)
 CLONAZEPAM† (compare to Klonopin®)
 CLONAZEPAM ODT† (compare to Klonopin Wafers®)
 CLORAZEPATE† (compare to Tranxene®)
 DIAZEPAM† (compare to Valium®)
 LORAZEPAM† (compare to Ativan®)
 MEPROBAMATE†
 OXAZEPAM† (compare to Serax®)

PA REQUIRED

Ativan®*
 Buspar®*
 Klonopin®*
 Klonopin Wafers®
 Librium®*
 Niravam® (alprazolam ODT)
 Serax®*
 Tranxene®* (all brand forms)
 Valium®*
 Xanax®*
 Xanax XR®

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTICOAGULANTS**LENGTH OF AUTHORIZATION: 6 MONTHS****QUANTITY LIMITS APPLY****NO PA REQUIRED**

WARFARIN (compare to Coumadin®)

HEPARIN

FRAGMIN® (dalteparin)

LOVENOX® (enoxaparin) (*QL = 2 syringes/day calculated in ml volume*)

ARIXTRA® (fondiparinux)

PA REQUIRED

Coumadin® (warfarin)

n/a

Innohep® (tinzaparin)

ANTICONVULSANTS**LENGTH OF AUTHORIZATION: LIFETIME FOR SEIZURE DISORDERS, DURATION OF NEED FOR MENTAL HEALTH INDICATIONS, 1 YEAR FOR OTHER INDICATIONS****NO PA REQUIRED**

CARBAMAZEPINE† (compare to Tegretol®)

CARBATROL® (carbamazepine)

CELONTIN® (methsuxamide)

CLONAZEPAM† (compare to Klonopin®)

CLONAZEPAM ODT† (compare to Klonopin Wafers®)

DEPAKOTE® (divalproex sodium)

DEPAKOTE ER® (divalproex sodium)

DIASTAT® (diazepam rectal gel)

DILANTIN® (phenytoin)

EPITOL† (carbamazepine)

ETHOSUXAMIDE† (compare to Zarontin®)

FELBATOL® (felbamate)

GABAPENTIN† (compare to Neurontin®)

GABITRIL® (tiagabine)

KEPPRA® (levetiracetam)

LAMICTAL® tabs (lamotrigine tabs)

LAMICTAL® chew tabs (lamotrigine chew tabs)

NEURONTIN® oral solution (gabapentin)

PEGANONE® (ethotoin)

PHENYTEK® (phenytoin)

PHENYTOIN† (compare to Dilantin®)

PRIMIDONE† (compare to Mysoline®)

TEGRETOL XR® (carbamazepine)

TOPAMAX® (topiramate)

TRILEPTAL® (oxcarbazepine)

VALPROIC ACID† (compare to Depakene®)

ZONISIMIDE† (compare to Zonegran®)

PA REQUIRED

Depakene®* (valproic acid)

Gabarone®* (gabapentin)

Klonopin®*

Klonopin Wafers®*

lamotrigine† chew tabs (compare to Lamictal® chew tabs)

Lyrica® (pregabalin) § (*Quantity Limit = 3 capsules/day*)

Mysoline®* (primidone)

Neurontin®* (gabapentin)

oxcarbazepine † (compare to Trileptal®)

Tegretol®* (carbamazepine)

Zarontin®* (ethosuxamide)

Zonegran®* (zonisamide)

PDL KEY:† **GENERIC PRODUCT*** **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTI-DEPRESSANTS: NOVEL

LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS, 1 YEAR FOR OTHER INDICATIONS

QUANTITY LIMITS APPLY

SUGGESTED DAILY DOSAGE LIMITS

NO PA REQUIRED

BUDEPRION®/BUPROPION SR† (compare to Wellbutrin SR®)
suggested max dose = 400 mg/day
 BUPROPION† (compare to Wellbutrin®)
 MAPROTILINE† (compare to Ludomil®)
 MIRTAZAPINE† (compare to Remeron®) *suggested max dose = 90 mg/day*
 MIRTAZAPINE RDT† (compare to Remeron Sol-Tab®) *suggested max dose = 90 mg/day*
 NEFAZADONE† (compare to Serzone®) *suggested max dose = 750 mg/day*
 TRAZODONE HCL† (compare to Desyrel®) *suggested max dose = 750 mg/day*
 WELLBUTRIN XL®

PA REQUIRED

Budeprion XR/bupropion XL† (compare to Wellbutrin XL®)
 Cymbalta®
 Desyrel®* *suggested max dose = 750 mg/day*
 Effexor®
 Effexor XR® § *suggested max dose = 450 mg/day, QL = 1 cap/day (37.5 mg & 75 mg caps)*
 Remeron®* *suggested max dose = 90 mg/day*
 Remeron Sol Tab®* *suggested max dose = 90 mg/day*
 venlafaxine IR §
 Wellbutrin®*
 Wellbutrin SR®* *suggested max dose = 400 mg/day*

ANTI-DEPRESSANTS: SSRIs

LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS, 1 YEAR FOR OTHER INDICATIONS

QUANTITY LIMITS APPLY

SUGGESTED DAILY DOSAGE LIMITS

NO PA REQUIRED

CITALOPRAM† (compare to Celexa®) *suggested max dose = 75 mg/day*
 FLUOXETINE† (compare to Prozac®) *suggested max dose = 100 mg/day*
 FLUVOXAMINE† (compare to Luvox®) *suggested max dose = 300 mg/day*
 PAROXETINE tablet† (compare to Paxil®) *suggested max dose = 75 mg/day*
 SERTRALINE† (compare to Zoloft®) *suggested max dose = 250 mg/day, QL = 1.5 tabs/day (25 mg & 50 mg tabs)*

PA REQUIRED

Celexa®* *suggested max dose = 75 mg/day*
 Lexapro® *suggested max dose = 25 mg/day, QL = 1.5 tabs/day (5 mg & 10 mg tabs)*
 Luvox®* *suggested max dose = 300 mg/day*
 paroxetine suspension† (compare to Paxil® susp) *suggested max dose = 75 mg/day*
 Paxil®* *suggested max dose = 75 mg/day*
 Paxil CR® *suggested max dose = 75 mg/day*
 Pexeva® *suggested max dose = 75 mg/day*
 Prozac®* *suggested max dose = 100 mg/day*
 Prozac Weekly® *suggested max weekly dose = 540 mg*
 Sarafem® *suggested max dose = 100 mg/day*
 Zoloft® *suggested max dose = 250 mg/day, QL = 1.5 tabs/day (25 mg & 50 mg tabs)*

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-DEPRESSANTS: TRICYCLICS

LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS, 1 YEAR FOR OTHER INDICATIONS

SUGGESTED DAILY DOSAGE LIMITS

NO PA REQUIRED

AMITRIPTYLINE† (compare to Elavil®) suggested max dose = 375 mg/day
AMITRIPTYLINE/CHLORDIAZ.† (compare to Limbitrol®)
AMITRIPTYLINE/PERPHEN†.(compare to Etrafon®, Triavil®)
AMOXAPINE† (compare to Asendin®)
CLOMIPRAMINE† (compare to Anafranil®)
DESIPRAMINE† (compare to Norpramin®)
DOXEPIN† (compare to Sinequan®)
IMIPRAMINE† (compare to Tofranil®) suggested max dose = 250 mg/day
NORTRIPTYLINE† (compare to Aventyl®, Pamelor®)
TOFRANIL PM® (imipramine pamoate)
TRIMIPRAMINE† (compare to Surmontil®)
VIVACTIL® (protriptyline)

PA REQUIRED

Anafranil®*
Aventyl®*
Elavil®*
Limbitrol®*
Limbitrol DS®
Norpramin®*
Pamelor®*
Sinequan®*
Surmontil®*
Tofranil®*

ANTI-DEPRESSANTS: MAO INHIBITORS

LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS

QUANTITY LIMITS APPLY

SUGGESTED DAILY DOSAGE LIMITS

NO PA REQUIRED

NARDIL® (phenylzine) suggested max dose = 110 mg/day
TRANLYLCYPROMINE† (compare to Parnate®) suggested max dose = 120 mg/day

PA REQUIRED

EMSAM® (selegiline) (QL = 1 patch/day)
Marplan® (isocarboxazid)
Parnate®*

ANTI-DIABETICS: ALPHA-GLUCOSIDASE INHIBITORS

LENGTH OF AUTHORIZATION: N/A

NO PA REQUIRED

GLYSET®(miglitol)
PRECOSE®(acarbose)

PA REQUIRED

ANTI-DIABETIC: BIGUANIDES & COMBINATIONS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

GLIPIZIDE/METFORMIN† (compare to Metaglip®)
GLYBURIDE/METFORMIN† (compare to Glucovance®)
METFORMIN† (compare to Glucophage®)
METFORMIN XR† (compare to Glucophage XR®)
RIOMET® (metformin oral solution)

PA REQUIRED

Fortamet®
Glucophage®*
Glucophage XR®*
Glucovance®*
Glumetza®
Metaglip®*

ANTI-DIABETICS: PEPTIDE HORMONES

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Byetta® (exenatide) § (Quantity Limit =1 pen/30 days)

PA REQUIRED

Symlin® (pramlintide) No Quantity Limit

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-DIABETICS: INSULINS

LENGTH OF AUTHORIZATION: LIFETIME

NO PA REQUIRED

RAPID-ACTING INJECTABLE

NOVOLOG® (Aspart)

SHORT-ACTING INJECTABLE

NOVOLIN R® (Regular)
RELION R® (Regular)

INTERMEDIATE-ACTING INJECTABLE

NOVOLIN N® (NPH)
RELION N® (NPH)

LONG-ACTING ANALOGS INJECTABLE

LANTUS® (insulin glargine)
LEVEMIR® (insulin detemir)

MIXED INSULINS INJECTABLE

HUMULIN 50/50® (NPH/Regular)
NOVOLIN 70/30® (NPH/Regular)
RELION 70/30® (NPH/Regular)

NOVOLOG MIX 70/30® (Protamine/Aspart)

HUMALOG MIX 50/50® (Protamine/Lispro)
HUMALOG MIX 75/25® (Protamine/Lispro)

INHALED

PA REQUIRED

Apidra® (insulin glulisine)
Humalog® (insulin lispro)

Humulin R® (Regular)

Humulin N® (NPH)

Humulin 70/30® (NPH/Regular)

Exubera® (insulin human [rDNA] Inhalation Powder)

ANTI-DIABETIC: ORAL MEGLITINIDES

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

STARLIX® (nateglinide)

PA REQUIRED

Prandin® (replaglinide)

ANTI-DIABETIC: SULFONYLUREAS 2ND GENERATION

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

GLIMEPIRIDE† (compare to Amaryl®)
GLIPIZIDE† (compare to Glucotrol®)
GLIPIZIDE ER† (compare to Glucotrol XL®)
GLYBURIDE† (compare to Diabeta®, Micronase®)
GLYBURIDE MICRONIZED† (compare to Glynase® PresTab®)

PA REQUIRED

Amaryl®*
Diabeta®*
Glucotrol®*
Glucotrol XL®*
Glynase® PresTab®*
Micronase®*

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTI-DIABETIC: THIAZOLIDINEDIONES & COMBINATIONS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

SINGLE AGENT

ACTOS® (pioglitazone) §

AVANDIA® (rosiglitazone) §

COMBINATION

ACTOPLUS MET® (metformin/pioglitazone) §

AVANDAMET® (metformin/rosiglitazone maleate) §

AVANDARYL® (glimepiride/rosiglitazone maleate) §

DUETACT® (pioglitazone/glimepiride) § (*Quantity Limit = 1 tablet/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ANTI-DIABETIC: DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

JANUVIA® (sitagliptin) § (*Quantity Limit = 1 tablet/day*)

JANUMET® (sitagliptin/metformin) § (*Quantity Limit = 2 tablets/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

ANTI-EMETICS: NK1/5HT3 ANTAGONISTS

LENGTH OF AUTHORIZATION: 6 MONTHS FOR CHEMOTHERAPY OR RADIOTHERAPY;

1 TIME FOR PREVENTION OF POST-OP NAUSEA/VOMITING: SEE CLINICAL CRITERIA.

MONTHLY QUANTITY LIMITS APPLY, PA REQUIRED TO EXCEED.

NO PA REQUIRED

EMEND® (aprepitant) 40 mg (1 cap/30 days)

*EMEND® (aprepitant) 80 mg (2 caps/30 days)

*EMEND® (aprepitant) 125 mg (1 cap/30 days)

*EMEND® (aprepitant) Tri-fold Pack (1 pack/30 days)

ONDANSETRON† Injection (vial and premix)

ONDANSETRON† tablet 4 mg (12 tabs/month), 8 mg (6 tabs/month)

ONDANSETRON† ODT 4 mg (12 tabs/month), 8 mg (6 tabs/month)

* To be prescribed by oncology practitioners ONLY

PA REQUIRED

Aloxi® (palonosetron, injectable) (2 vials/month)

Anzemet® (dolansetron) 50 mg (4 tabs/month)

Anzemet® (dolansetron) 100 mg (2 tabs/month)

Kytril® (gransetron) 1 mg (6 tabs/month)

Kytril® (gransetron) Injectable

Ondansetron† (generic) 24 mg (1 tab/month)

Ondansetron† (generic) Oral Solution 4 mg/5 ml

Zofran®* (ondansetron) Injection

Zofran®* (ondansetron) Oral Tablets and ODT 4 mg (12 tabs/month), 8 mg (6 tabs/month)

Zofran® (ondansetron) 24 mg (1 tab/month)

Zofran® (ondansetron) Oral Solution 4 mg/5 ml

ANTI-EMETICS: OTHER

LENGTH OF AUTHORIZATION: INITIAL APPROVAL 3 MONTHS, SUBSEQUENT APPROVAL UP TO 6 MONTHS

QUANTITY LIMITS APPLY

NO PA REQUIRED

PA REQUIRED

Marinol® (dronabinol) (*Quantity Limit = 30 days supply for AIDS anorexia or quantity required for one chemotherapy treatment course*)

Cesamet® (nabilone) (*Quantity Limit = quantity required for one chemotherapy treatment course*)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTIHYPERKINESIS: ADHD, ADD, NARCOLEPSY**LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS, 1 YEAR FOR OTHER INDICATIONS****CNS STIMULANTS (ALL FORMS SHORT- & LONG-ACTING): PA'D FOR BENEFICIARIES < 3 YRS****QUANTITY LIMITS APPLY****NO PA REQUIRED****SHORT/INTERMEDIATE ACTING METHYLPHENIDATE PREPS**

METADATE ER® (compare to Ritalin® SR)
 METHYLIN® (compare to Ritalin®)
 METHYLIN® ER (compare to Ritalin® SR)
 METHYLPHENIDATE† (compare to Ritalin®)
 METHYLPHENIDATE SR† (compare to Ritalin® SR)

PA REQUIRED

Dexmethylphenidate (compare to Focalin®)
 Focalin® (dexmethylphenidate)
 Ritalin®*
 Ritalin SR®*

LONG-ACTING METHYLPHENIDATE PREPS

FOCALIN® XR (dexmethylphenidate IR/ER, 50:50%)
 CONCERTA® (methylphenidate IR/ER 22:78%)

Metadate CD® (methylphenidate, IR/ER, 30:70%)
 Ritalin LA® (methylphenidate, IR/ER, 50:50%)
 Daytrana® (methylphenidate patch) (*QL = 1 patch/day*)

SHORT/INTERMEDIATE AMPHETAMINE PREPS

AMPHETAMINE salt combination† (compare to Adderall®)
 DEXTROAMPHETAMINE†
 DEXTROAMPHETAMINE CR† (compare to Dexedrine CR®)
 DEXTROSTAT†

Adderall®*
 Desoxyn® (methamphetamine)
 Dexedrine®* (CR)

LONG-ACTING AMPHETAMINE PREPS

ADDERALL XR® (dextroamphetamine IR/ER, 50:50%)

NON-STIMULANT PREPS

Provigil® (modafinil) (**not approvable for ADHD in children age ≤ 12**)
 Strattera® (atomoxetine) *max dose = 100 mg/day*

 Xyrem® (sodium oxybate)

ANTI-HYPERTENSIVES: ACE INHIBITORS**LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**

BENAZEPRIL† (compare to Lotensin®)
 CAPTOPRIL† (compare to Capoten®)
 ENALAPRIL† (compare to Vasotec®)
 FOSINOPRIL† (compare to Monopril®)
 LISINOPRIL† (compare to Zestril®, Prinivil®)
 MOEXIPRIL† (compare to Univasc®)
 QUINAPRIL† (compare to Accupril®)

PA REQUIRED

Accupril®*
 Aceon® (perindopril)
 Altace® (ramipril)
 Capoten®*
 Lotensin®*
 Mavik® (trandolapril)
 Monopril®*

Prinivil®*
 trandolapril† (compare to Mavik®)
 Univasc®* (moexipril)
 Vasotec®*
 Zestril®*

PDL KEY:**† GENERIC PRODUCT***** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA****§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTI-HYPERTENSIVES: ACE INHIBITOR WITH HYDROCHLOROTHIAZIDE

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

BENAZEPRIL/HYDROCHLOROTHIAZIDE† (compare to Lotensin HCT®)
CAPTOPRIL/HYDROCHLOROTHIAZIDE† (compare to Capozide®)
ENALAPRIL/HYDROCHLOROTHIAZIDE† (compare to Vaseretic®)
FOSINOPRIL/HYDROCHLOROTHIAZIDE† (compare to Monopril HCT®)
LISINOPRIL/HYDROCHLOROTHIAZIDE† (compare to Zestoretic®, Prinzide®)
QUINAPRIL/HYDROCHLOROTHIAZIDE† (compare to Accuretic®)

PA REQUIRED

Accuretic®*
Capozide®*
Lotensin HCT®*
moexipril/hydrochlorothiazide† (compare to Uniretic®)
Monopril HCT®*
Prinzide®*
Uniretic® (moexipril/hydrochlorothiazide)
Vaseretic®*
Zestoretic®*

ANTI-HYPERTENSIVES: ACE INHIBITOR W/CALCIUM CHANNEL BLOCKER

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

benazepril/amlodipine † (compare to Lotrel®)

PA REQUIRED

Lexxel® (enalapril/felodipine)
Lotrel® (benazepril/amlodipine)
Tarka® (trandolopril/verapamil)

ANTI-HYPERTENSIVES: ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

LENGTH OF AUTHORIZATION: LIFETIME

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

AVAPRO® (irbesartan) §
BENICAR® (olmesartan) §
COZAAR® (losartan) §
DIOVAN® (valsartan) §
MICARDIS® (telmisartan) §

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Atacand® (candesartan) §
Teveten® (eprosartan) §

ANTI-HYPERTENSIVES: ANGIOTENSIN RECEPTOR BLOCKER/HYDROCHLOROTHIAZIDE COMBINATIONS

LENGTH OF AUTHORIZATION: LIFETIME

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

AVALIDE® (irbesartan/hydrochlorothiazide) §
BENICAR HCT® (olmesartan/hydrochlorothiazide) §
DIOVAN HCT® (valsartan/hydrochlorothiazide) §
HYZAAR® (losartan/hydrochlorothiazide) §
MICARDIS HCT® (telmisartan/hydrochlorothiazide) §

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Atacand HCT® (candesartan/hydrochlorothiazide) §
Teveten HCT® (eprosartan/hydrochlorothiazide) §

ANTI-HYPERTENSIVES: ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER COMBINATIONS

LENGTH OF AUTHORIZATION: N/A

QUANTITY LIMITS APPLY

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

EXFORGE® (valsartan/amlodipine) § (*Quantity Limit = 1 tablet/day*)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-HYPERTENSIVES: BETA BLOCKERS

LENGTH OF AUTHORIZATION: 5 YEARS

NO PA REQUIRED

SINGLE AGENT

ACEBUTOLOL† (compare to Sectral®)
 ATENOLOL† (compare to Tenormin®)
 BETAXOLOL† (compare to Kerlone®)
 BISOPROLOL FUMARATE† (compare to Zebeta®)
 CARVEDILOL† (compare to Coreg®)
 LABETALOL† (compare to Normodyne®, Trandate®)
 METOPROLOL† (compare to Lopressor®)
 METOPROLOL XL† (compare to Toprol XL®)
 NADOLOL† (compare to Corgard®)
 PINDOLOL† (compare to Visken®)
 PROPRANOLOL† (compare to Inderal®)
 SOTALOL† (compare to Betapace®, Betapace AF®)
 TIMOLOL† (compare to Blocadren®)

BETA-BLOCKER/DIURETIC COMBINATION

ATENOLOL/CHLORTHALIDONE † (compare to Tenoretic®)
 BISOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Ziac®)
 METOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Lopressor HCT®)
 PROPRANOLOL/HYDROCHLOROTHIAZIDE† (compare to Inderide®)

PA REQUIRED

Betapace®*
 Betapace AF®*
 Blocadren®*
 Cartrol®
 Coreg®
 Coreg CR®
 Corgard®
 Inderal®* (all products)
 Inderal LA®
 Innopran XL®
 Kerlone®*
 Levatol® (penbutolol)
 Lopressor®* (all products)
 propranolol ER† (compare to
 Inderal LA®)
 Sectral®*
 Tenormin®*
 Timolide®
 Toprol XL®* (metoprolol succinate)
 Trandate®*
 Zebeta®*

Corzide®
 Inderide®*
 Lopressor HCT®*
 Nadolol/bendroflumethiazide†
 (compare to Corzide®)
 Tenoretic®*
 Ziac®*

ANTI-HYPERTENSIVES: CALCIUM CHANNEL BLOCKERS

LENGTH OF AUTHORIZATION: 5 YEARS

QUANTITY LIMITS APPLY

NO PA REQUIRED

AMLODIPINE† (compare to Norvasc®)
 CARTIA XT® (diltiazem HCL)
 DILTIA XT® (diltiazem HCL)
 DILTIAZEM† (compare to Cardizem®)
 DILTIAZEM ER† (compare to Cardizem® SR)
 DILTIAZEM CD† (compare to Cardizem® CD)
 DILTIAZEM XR† (compare to Dilacor® XR)
 FELODIPINE† (compare to Plendil®)
 NICARDIPINE† (compare to Cardene®)
 NIFEDIAC® CC (compare to Adalat CC®)
 NIFEDICAL XL† (compare to Procardia® XL)
 NIFEDIPINE IR† (compare to Procardia®)
 NIFEDIPINE ER† (compare to Procardia® XL)
 NIMODIPINE† (compare to Nimotop®)
 TAZTIA XT® (compare to Tiazac®)
 VERAPAMIL† (compare to Calan®)
 VERAPAMIL CR† (compare to Calan SR®, Isoptin SR®)
 VERAPAMIL SR† 120 mg, 180 mg 240 mg and 360 mg (compare to
 Verelan®)

EXFORGE® (valsartan/amlodipine) § (Quantity Limit = 1 tablet/day)

PA REQUIRED

Adalat® CC*
 Calan®*
 Calan® SR*
 Cardene®*
 Cardene® SR (no AB rated generic)
 Cardizem®*, Cardizem® CD*
 Cardizem® LA (no AB rated generic)
 Covera-HS® (no AB rated generic)
 Dilacor® XR*
 Dynacirc CR® (no AB rated generic)
 Isoptin® SR*
 isradipine†
 Nimotop®* (nimodipine)
 Norvasc®* (amlodipine)
 Plendil®*
 Procardia®*
 Procardia® XL*
 Sular® (nisoldipine)
 Tiazac®*
 verapamil SR †100 mg, 200 mg, 300mg (compare to Verelan PM®)
 Verelan®*
 Verelan PM®
 Caduet® (amlodipine/atorvastatin)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG
 THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-HYPERTENSIVES: RENIN INHIBITOR**LENGTH OF AUTHORIZATION: LIFETIME****PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**

TEKTURNA® (aliskiren) §

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**ANTI-INFECTIVES: CEPHALOSPORINS – 1ST GENERATION****LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS****NO PA REQUIRED**CEFADROXIL† (compare to Duricef®)
CEPHALEXIN† (compare to Keflex®)

IV drugs are not managed at this time

PA REQUIREDDuricef®*
Keflex®***ANTI-INFECTIVES: CEPHALOSPORINS – 2ND GENERATION****LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, ONLY: NO REFILLS****NO PA REQUIRED****TABLETS**
CEFACLOR CAPSULE†
CEFACLOR ER TABLET†
CEFPROZIL TABLET† (compare to Cefzil®)
CEFUROXIME TABLET† (compare to Ceftin®)**PA REQUIRED**Ceftin®* tablet
Cefzil® tablet
Lorabid® (loracarbef) capsule**SUSPENSION**CEFACLOR SUSPENSION†
CEFPROZIL SUSPENSION† (compare to Cefzil®)
CEFTIN® (cefuroxime) SUSPENSIONCefzil® suspension
Lorabid® (loracarbef) suspension

IV drugs are not managed at this time

ANTI-INFECTIVES: CEPHALOSPORINS – 3RD GENERATION**LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS****NO PA REQUIRED****CAPSULES/TABLETS**
CEFPODOXIME PROXETIL TABS† (compare to Vantin®)
OMNICEF® CAPSULE (cefdinir)**PA REQUIRED**Cedax® capsule (ceftibuten)
cefdinir capsule†
Spectracef® tablet (cefditoren)
Vantin®* tablet (cefpodoxime)**SUSPENSION**OMNICEF® SUSPENSION (cefdinir)
SUPRAX® SUSPENSION (cefixime)Cedax® suspension (ceftibuten)
cefdinir suspension †
cefpodoxime proxetil† (compare to Vantin®) suspension
Vantin® suspension (cefpodoxime)

IV drugs are not managed at this time

ANTI-INFECTIVES: KETOLIDES**LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS****NO PA REQUIRED****PA REQUIRED**

Ketek® (telithromycin)

PDL KEY:**† GENERIC PRODUCT***** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA****§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTI-INFECTIVES: MACROLIDES

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS

NO PA REQUIRED

AZITHROMYCIN† tablets (\leq 5 day supply) (compare to Zithromax®)
AZITHROMYCIN† liquid (\leq 5 day supply) (compare to Zithromax®)

CLARITHROMYCIN† (compare to Biaxin/Biaxin XL)

ERY-TAB® (erythromycin base, delayed release)
ERYTHROCIN† (erythromycin stearate)
ERYTHROMYCIN BASE†
ERYTHROMYCIN ESTOLATE†
ERYTHROMYCIN ETHYLSUCCINATE† (compare to E.E.S.®, Eryped®)
ERYTHROMYCIN STEARATE†
ERYTHROMYCIN W/ SULFASOXAZOLE† (compare to Pedazole®)
IV drugs are not managed at this time

PA REQUIRED

azithromycin† tablets and liquid (if $>$ 5 day supply)
Biaxin®*
Biaxin XL®
Dynabac® (dirithromycin)
E.E.S.®*
Eryc®* (erythromycin base, delayed release)
Eryped® (erythromycin ethylsuccinate)
PCE DisperTab® (erythromycin base)
Pedazole®* (erythromycin-sulfisoxazole)
Zithromax® tablets and liquid
Zmax® (azithromycin extended release oral suspension)

ANTI-INFECTIVES: OXAZOLIDINONES

LENGTH OF AUTHORIZATION: 28 DAYS, NO REFILLS

QUANTITY LIMITS APPLY

NO PA REQUIRED

IV form of this medication not managed at this time

PA REQUIRED

Zyvox® (linezolid) (QL = 56 tablets per 28 days)

ANTI-INFECTIVES: PENICILLINS (ORAL)

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS

NO PA REQUIRED

AMOXICILLIN† (compare to Amoxil®, Trimox®, DisperMox™)
AMOXICILLIN/CLAVULANATE† (compare to Augmentin®)
AMPICILLIN† (compare to Principen®)
DICLOXA CILLIN†
PENICILLIN VK† (compare to Veetids®)

PA REQUIRED

Augmentin®*
Augmentin ES®*
Augmentin XR®

* PA will be granted for 125 mg/5 mL strength for patients $<$ 12 weeks of age

ANTI-INFECTIVES: QUINOLONES

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS

NO PA REQUIRED

CIPROFLOXACIN† (compare to Cipro®)
CIPRO® OS (ciprofloxacin oral solution) 100 mg/ml
LEVAQUIN® (levofloxacin)
OFLOXACIN†

PA REQUIRED

Avelox® (moxifloxacin HCL)
Avelox ABC PACK® (moxifloxacin HCL)
Cipro®*
Cipro XR®
ciprofloxacin ER†
Factive® (gemifloxacin)
Noroxin® (norfloxacin)
ProQuin XR® (ciprofloxacin)

IV drugs are not managed at this time

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-INFECTIVES: ONYCHOMYCOSIS AGENTS

LENGTH OF AUTHORIZATION: 1 YEAR, SEE CLINICAL CRITERIA.

MONTHLY QUANTITY LIMITS APPLY

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

CICLOPIROX† Nail Lacquer (compare to Penlac®) *QL = 6.6 ml/90 days*
TERBINAFINE† tabs (compare to Lamisil®) *QL = 30 tablets/month*

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Lamisil® tablets (terbinafine HCL) *QL = 30 tablets/month*
Penlac® Nail Lacquer (ciclopirox) *QL = 6.6 ml/90 days*
Sporanox® (itraconazole) *QL = 28 capsules/month (brand & generic)*

ANTI-INFECTIVES: ANTI-VIRALS: HERPES

LENGTH OF AUTHORIZATION: FOR DURATION OF PRESCRIPTION, UP TO 6 MONTHS.

NO PA REQUIRED

ACYCLOVIR† (compare to Zovirax®)
VALTREX® (valacyclovir)

PA REQUIRED

Famciclovir † (compare to Famvir®)
Famvir® (famciclovir) §
Zovirax®* §

ANTI-INFECTIVES: GENITAL ANTIVIRALS

LENGTH OF AUTHORIZATION: 1 MONTH

NO PA REQUIRED

ALDARA® (imiquimod)
CONDYLOX® GEL (podofilox gel)
PODOFILOX SOLUTION† (compare to Condylox®)

PA REQUIRED

Condylor®* solution (podofilox solution)

ANTI-INFECTIVES: INFLUENZA MEDICATIONS

LENGTH OF AUTHORIZATION: FOR DURATION OF PRESCRIPTION, UP TO 3 MONTHS.

QUANTITY LIMITS APPLY

NO PA REQUIRED (DURING FLU SEASON NOV 1ST – MARCH 31ST)

RELENTA® (zanamivir) *QL= 20 blisters / 30 days*
TAMIFLU® (oseltamivir) *QL=10 capsules/30 days(45 mg & 75 mg caps)
20 capsules / 30 days (30 mg caps)
75 ml /30 days (suspension)*

PA REQUIRED

amantadine† PA for quantity ≤ 10 days supply (*Not CDC recommended for use in influenza*)
Flumadine® (rimantadine) (*Not CDC recommended for use in influenza*)
rimantadine† (*Not CDC recommended for use in influenza*)
Symmetrel® (amantadine) (*Not CDC recommended for influenza*)

ANTI-INFECTIVES: INFLUENZA VACCINES

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE ONLY

NO PA REQUIRED

AFLURIA® Injection
FLUARIX® Injection
FLUZONE® Injection
FLUVIRIN® Injection

PA REQUIRED

FluMist® Nasal

ANTI-INFECTIVES: MISCELLANEOUS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

PA REQUIRED

Qualaquin® (quinine sulfate)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

ANTI-INFECTIVES: TOPICAL ANTIBIOTICS

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS

QUANTITY LIMITS APPLY

NO PA REQUIRED

BACITRACIN†
 GENTAMICIN†
 BACITRACIN-POLYMICIN†
 NEOMYCIN-BACITRACIN-POLYMICIN†
 CORTISPORIN®
 BACTROBAN® OINTMENT
 MUPIROCIN OINTMENT (compare to Bactroban®)

PA REQUIRED

Altabax® (retapamulin) (*Quantity Limit = 1 tube*)
 Bactroban® CREAM

ANTI-MIGRAINE: TRIPTANS

LENGTH OF AUTHORIZATION: 6 MONTHS

MONTHLY QUANTITY LIMITS APPLY, PA REQUIRED TO EXCEED.

NO PA REQUIRED, QUANTITY LIMITS APPLY

AXERT® (almotriptan) 6.25 mg, 12.5 mg (*QL = 6 tabs/month*)
 IMITREX® (sumatriptan) Injection 6 mg (*QL = 4 injections/month*)
 IMITREX® NS (sumatriptan) 20 mg (*QL = 6 units/month*)
 IMITREX® NS (sumatriptan) 5 mg (*QL = 12 units/month*)
 IMITREX® (sumatriptan) 25 mg (*QL = 18 tabs/month*)
 IMITREX® (sumatriptan) 50 mg, 100 mg (*QL = 9 tabs/month*)
 MAXALT-MLT® (rizatriptan ODT) 5 mg, 10 mg (*QL = 12 tabs/month*)
 MAXALT® (rizatriptan) 5 mg, 10 mg (*QL = 12 tabs/month*)

PA REQUIRED, QUANTITY LIMITS APPLY

Amerge® (naratriptan) 1 mg, 2.5 mg (*QL = 9 tabs/month*)
 Frova® (frovatriptan) 2.5 mg (*QL = 9 tabs/month*)
 Relpax® (eletriptan) 20 mg, 40 mg (*QL = 12 tabs/month*)
 Zomig® (zolmitriptan) ZMT 2.5 mg (*QL = 12 tabs/month*),
 5 mg (*QL = 6 tabs/month*)
 Zomig® 2.5 mg (*QL = 12 tabs/month*)
 Zomig® 5 mg (*QL = 6 tabs/month*)
 Zomig® Nasal Spray (*QL = 12 units/month*)

ANTI-OBESITY

LENGTH OF AUTHORIZATION: 6 MONTHS FOR INITIAL APPROVAL,

MAY RENEW FOR ADDITIONAL 6 MONTHS IF PATIENT HAS MET TARGET GOALS.

THERAPY SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.

NO PA REQUIRED

PA REQUIRED

benzphetamine† (all forms brand & generic)
 diethylpropion† (all forms brand & generic)
 Meridia® (sibutramine)
 phentermine† (all forms brand & generic)
 phendimetrazine† (all forms brand & generic)
 Xenical® (orlistat)

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

ANTI-PSYCHOTIC: ATYPICAL & COMBINATIONS

LENGTH OF AUTHORIZATION: DURATION OF NEED

QUANTITY LIMITS APPLY

SUGGESTED DAILY DOSAGE LIMITS

NO PA REQUIRED

CLOZAPINE† (compare to Clozarin®) suggested max dose = 1125 mg/day

GEODON® (ziprasidone) suggested max dose = 200 mg/day

RISPERDAL® (risperidone) suggested max dose = 10 mg/day

SEROQUEL® (quetiapine) suggested max dose = 1000 mg/day

RISPERDAL® (risperidone) oral solution suggested max dose=10 mg/day

GEODON IM® (ziprasidone Injectable)

PA REQUIRED

Abilify® (aripiprazole) suggested max dose = 40 mg/day,
QL = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)

Clozaril®* suggested max dose = 1125 mg/day

Invega® (paliperidone) QL = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)

Zyprexa® (olanzapine) suggested max dose = 50 mg/day,
QL = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg, & 10 mg tabs)

Abilify® (aripiprazole) oral solution suggested max dose = 40 mg/day

Abilify® IM (aripiprazole intramuscular injection)

Zyprexa® IM (olanzapine intramuscular injection)

Risperdal Consta® (risperidone microspheres)

Abilify Discmelt (aripiprazole) suggested max dose = 40 mg/day, Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)

Fazaclor® (clozapine orally disintegrating tablet) suggested max dose = 1125 mg/day

Risperdal M-Tab® (risperidone orally disintegrating tablet) suggested max dose = 10 mg/day

Zyprexa Zydis® (olanzapine orally disintegrating tablet) suggested max dose = 50 mg/day, QL = 1.5 tabs/day (5 mg & 10 mg tabs)

Symbax® (olanzapine/fluoxetine)

ANTI-PSYCHOTIC: TYPICALS

LENGTH OF AUTHORIZATION: DURATION OF NEED FOR MENTAL HEALTH INDICATIONS

NO PA REQUIRED

CHLORPROMAZINE† (compare to Thorazine®)

FLUPHENAZINE† (compare to Prolixin®, Prolixin®)

HALOPERIDOL† (compare to Haldol®)

LOXAPINE† (compare to Loxitane®)

MOBAN® (molindone)

PERPHENAZINE† (compare to Trilafon®)

THIORIDAZINE† (compare to Mellaryl®)

THIOTHIXENE† (compare to Navane®)

TRIFLUOPERAZINE† (compare to Stelazine®)

PA REQUIRED

Haldol®*

Loxitane®*

Mellaril®*

Navane®*

Prolixin®*

Thorazine®*

Trilafon®*

BOTULINUM TOXINS

LENGTH OF AUTHORIZATION: INITIAL APPROVAL 3 MONTHS, SUBSEQUENT APPROVAL UP TO 12 MONTHS

NO PA REQUIRED

PA REQUIRED

Botox®

Botox® Cosmetic

Myobloc®

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

BPH: ALPHA BLOCKERS**LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**

DOXAZOSIN† (compare to Cardura®)
 FLOMAX® (tamsulosin)
 TERAZOSIN† (compare to Hytrin®)
 UROXATRAL® (alfuzosin)

PA REQUIRED

Cardura®*, Cardura XL®
 Hytrin®*

BPH: ANDROGEN HORMONE INHIBITORS**LENGTH OF AUTHORIZATION: LIFETIME****NO PA REQUIRED**

AVODART® (dutasteride)
 FINASTERIDE† (compare to Proscar®)
 PROSCAR® (finasteride)

PA REQUIRED

Avodart® (dutasteride) females; males age < 45
 finasteride† (compare to Proscar®) females; males age < 45
 Proscar® (finasteride) females; males age < 45

CARDIAC GLYCOSIDES**LENGTH OF AUTHORIZATION: N/A****NO PA REQUIRED**

DIGITEK® (digoxin)
 DIGOXIN†
 LANOXICAPS® (digoxin)
 LANOXIN® (digoxin)

PA REQUIRED**CHEMICAL DEPENDENCY: ALCOHOL AND OPIATE DEPENDENCY****LENGTH OF AUTHORIZATION: VIVITROL – 6 MONTHS, NO RENEWAL, ALL OTHERS 1 YEAR****DATA 2000 WAIVER ("X" NUMBER) REQUIRED FOR PRESCRIBERS OF BUPRENORPHINE****QUANTITY LIMITS APPLY****VIVITROL AND BUPRENORPHINE THERAPY SPECIFIC PA FAX FORMS ARE AVAILABLE ON OVHA WEBSITE.****NO PA REQUIRED****Alcohol Dependency**

ANTABUSE® (disulfiram)
 CAMPRAL® (acamprosate)
 NALTREXONE oral † (compare to Revia®)

PA REQUIRED

Revia®* (naltrexone oral)

Vivitrol® (naloxone for extended-release injectable suspension) (*QL = 1 injection (380 mg) per 30 days*)

Opiate Dependency

NALTREXONE oral † (compare to Revia®)

Revia®* (naltrexone oral)

Suboxone® (buprenorphine with naloxone): 2 mg/0.5 mg and 8 mg/2 mg tablet
 Subutex® (buprenorphine): 2 mg and 8 mg tablets

Note: Methadone for opiate dependency can only be prescribed through a
 Methadone Maintenance Clinic

CONSTIPATION: CHRONIC**LENGTH OF AUTHORIZATION: 3 MONTHS****NO PA REQUIRED****Bulk-Producing Laxatives**

PSYLLIUM†

Osmotic Laxatives

LACTULOSE†

POLYETHYLENE GLYCOL 3350 (PEG)† (compare to Miralax®)

PA REQUIRED

Amitiza® (lubiprostone)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

COUGH AND COLD PREPARATIONS

LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS

EFFECTIVE JUNE 1, 2006

NO PA REQUIRED

All generics
MUCINEX® (guaifenesin)

PA REQUIRED

All brands

CORONARY VASODILATORS/ANTIANGINALS: ORAL

LENGTH OF AUTHORIZATION: 3 YEARS

QUANTITY LIMITS APPLY

NO PA REQUIRED

ISOSORBIDE DINITRATE† tablet(compare to Isordil®)
ISOSORBIDE DINITRATE† SL tablet
ISOSORBIDE DINITRATE† ER tablet
ISOSORBIDE MONONITRATE† tablet (compare to Ismo®, Monoket®)
ISOSORBIDE MONONITRATE† ER tablet (compare to Imdur®)
NITROGLYCERIN† SL tablet
NITROGLYCERIN† ER capsule
NITROLINGUAL PUMP SPRAY®
NITROGARD® BUCCAL
NITROQUICK® (nitroglycerin SL tablet)
NITROSTAT®(nitroglycerin SL tablet)
NITRO-TIME® (nitroglycerin ER capsule)

PA REQUIRED

Dilatrate-SR® (isosorbide dinitrate SR capsule)
Imdur®* (isosorbide mononitrate ER tablet)
Ismo®* (isosorbide mononitrate tablet)
Isordil®* (isosorbide dinitrate tablet)
Monoket®* (isosorbide mononitrate tablet)

BiDil® (isosorbide dinitrate/hydralazine)

Ranexa® (ranolazine) (*Quantity Limit = 3 tablets/day (500 mg), 2 tablets/day (1000 mg))*)

CORONARY VASODILATORS/ANTIANGINALS: TOPICAL

LENGTH OF AUTHORIZATION: 3 YEARS

NO PA REQUIRED

NITREK® (nitroglycerin transdermal patch)
NITRO-BID® (nitroglycerin ointment)
NITROGLYCERIN TRANSDERMAL PATCHES† (compare to Nitro-Dur®)

PA REQUIRED

Nitro-Dur®* (nitroglycerin transdermal patch)

GASTROINTESTINAL: CROHN'S DISEASE INJECTABLES

LENGTH OF AUTHORIZATION: INITIAL PA 3 MONTHS; 12 MONTHS THEREAFTER

THERAPY-SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

HUMIRA® (adalimumab)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Remicade® (infliximab)

GASTROINTESTINALS: H2-BLOCKERS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

CIMETIDINE† (compare to Tagamet®) tablet
FAMOTIDINE† (compare to Pepcid®) tablet
RANITIDINE† (compare to Zantac®) tablet

PA REQUIRED

Axid® (nizatidine) capsule §
nizatidine† (compare to Axid®) capsule §
Pepcid®* (famotidine) tablet §
ranitidine† capsule §
Tagamet®* tablet §
Zantac®* tablet §

SYRUPS AND SPECIAL DOSAGE FORMS

CIMETIDINE † ORAL SOLUTION
ZANTAC® (ranitidine) SYRUP

Axid® (nizatidine) Oral Solution §
Pepcid® Oral Suspension §
ranitidine† syrup§
Zantac Effervescent® §

PDL KEY:

† GENERIC PRODUCT

*** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

GASTROINTESTINALS: PROTON PUMP INHIBITORS

LENGTH OF AUTHORIZATION: UP TO 1 YEAR

QUANTITY LIMITS APPLY

NO PA REQUIRED FOR ONCE DAILY DOSES

PREVACID® (lansoprazole) capsules (*Quantity Limit=1 capsule/day*)

PREVACID® (lansoprazole) packets (*Quantity Limit=1 packet/day*)

PRILOSEC OTC® (omeprazole) *No Quantity Limit*

PROTONIX® (pantoprazole) (*Quantity Limit=1 tablet/day*)

H.Pylori eradication

PREVPAC® (lansoprazole w/ H.pylori anti-bacterials) *No Quantity Limit*

♦ No PA required for patients <16 years; Quantity Limits still apply.

▲ No PA required for patients < 12 years; Quantity Limits still apply.

PA REQUIRED

AcipHex® (rabeprazole) § Qty Limit=1 tablet/day

Nexium® (esomeprazole) capsules§ Qty Limit=1 capsule/day

Nexium® (esomeprazole) powder for suspension § (Qty limit=1 packet/day)

omeprazole generic♣ § Qty Limit=1 capsule/day

Prevacid Solutabs®▲ Qty Limit=1 tablet/day

Prilosec® (brand) § Qty Limit=1 capsule/day

Zegerid®♣ (omeprazole powder for suspension) § Qty Limit=1 powder packet/day

Zegerid® (omeprazole capsules) § Qty Limit=1 capsule/day

GASTROINTESTINAL: ULCERATIVE COLITIS INJECTABLES

LENGTH OF AUTHORIZATION: INITIAL PA 3 MONTHS; 12 MONTHS THEREAFTER

THERAPY-SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.

NO PA REQUIRED

PA REQUIRED

Remicade® (infliximab)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

GLUCOCORTICOIDS: TOPICAL

LENGTH OF AUTHORIZATION: DURATION OF PRESCRIPTION, UP TO 6 MONTHS.

NO PA REQUIRED

ALCLOMETASONE† (compare to Aclovate®)
DESONIDE† (compare to Tridesilon®)
FLUOCINOLONE 0.01%† (compare to Synalar®)
HYDROCORTISONE ACETATE† (all generics)

PA REQUIRED

Low Potency

Aclovate®*
Cortaid®*
Desonate® gel (desonide)
DesOwen®*
Hytone®*
Synalar® 0.01% * (all products)
Tridesilon®*
Verdeso® (desonide foam)
All other brands

Medium Potency

BECLOMETHASONE DIPROPIONATE† (compare to Alphatrex®)
BETAMETHASONE VALERATE† (compare to Beta-Val®)
DESOXIMETASONE 0.05%† (compare to Topicort®)
FLUOCINOLONE 0.025%† (compare to Synalar®)
FLUTICASONE TOPICAL† (compare to Cutivate®)
HYDROCORTISONE BUTYRATE† (compare to Locoid®)
HYDROCORTISONE VALERATE† (compare to Westcort®)
MOMETASONE FUROATE† (compare to Elocon®)
TRIAMCINOLONE ACETONIDE† (compare to Aristocort®)

Alphatrex®*
Aristocort®* (all products)
Beta-Val®*
Cloderm® (clocortolone)
Cordran®* (all products)
Cutivate®*
Dermatop®
Elocon®* (all products)
Kenalog® (all products)
Locoid®
Luxiq®
prednizolone† (compare to Dermatop®)
Pandel®
Synalar® 0.025 %* (all products)
Topicort® 0.05 %* (all products)
Westcort®* (all products)
All other brands

High Potency

AMCINONIDE† (compare to Cyclocort®)
AUGMENTED BETHAMETHASONE CREAM† (compare to Diprolene® AF)
DESOXIMETASONE 0.25%† (compare to Topicort®)
DIFLORASONE DIACETATE† (compare to Apexicon®, Maxiflora®, Psorcon-E®)
FLUOCINOLONE 0.2%† (compare to Synalar®)
FLUOCINONIDE† (compare to Lidex®)

Apexicon®*
Cyclocort®*
Diprolene® AF* (all products)
Halog®* (all products)
Lidex®* (all products)
Maxiflora®*
Synalar® 0.2 %* (all products)
Topicort® 0.25 %* (all products)
Vanos®
All other brands

Very High Potency

AUGMENTED BETHAMETHASONE OINTMENT† (compare to Diprolene®)
CLOBETASOL PROPIONATE† (compare to Temovate®)
DIFLORASONE DIACETATE EMOLL† (compare to Psorcon®)
HALOBETASOL PROPRIONATE† (compare to Ultravate®)

Clobex®
Cormax®
Diprolene®* (all products)
Emoline E®*
Olux®/Olux E®
Psorcon®*
Temovate®* (all products)
Ultravate®* (all products)
All other brands

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

GROWTH STIMULATING AGENTS

**LENGTH OF AUTHORIZATION: 6 MONTHS INITIALLY, THEN UP TO 1 YEAR; SHORT BOWEL SYNDROME = 4 WEEKS.
AGENTS AVAILABLE AFTER CLINICAL CRITERIA ARE MET.**

THERAPY SPECIFIC PA FORM IS AVAILABLE ON OVHA WEBSITE.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

NORDITROPIN®
NUTROPIN®
NUTROPIN® Depot

OMNITROPE®

INCRELEX® (mecasermin)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Genotropin®
Humatropin®
Saizen®
Serostim®
Tev-Tropin®

Zorbtive® (with special criteria)

HEPATITIS C AGENTS

LENGTH OF AUTHORIZATION: 6 MONTHS

THERAPY SPECIFIC PA FORM IS AVAILABLE ON OVHA WEBSITE.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

RIBAVIRIN
RIBAVIRIN†

INTERFERON

PEGASYS® (peg-interferon alpha 2-a) (*QL* = 4 vials/28 days)
PEGASYS CONVENIENCE PACK® (peg-interferon alfa-2a) (*QL* = 1 kit/28 days)

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

RIBAVIRIN
Copegus®
Ribasphere®
Rebetol®
INTERFERON
Infergen® (interferon alphacon-1)
Peg-Intron® (peg-interferon alpha-2b)
COMBINATION
Rebetron® (Rebetol/Intron-A)

IMMUNOMODULATORS: TOPICAL

****CAUTION NOT APPROVED FOR USE IN CHILDREN UNDER 2 YEARS OLD****

EFFECTIVE 11/1/06: PA REQUIRED FOR ELIDEL / PROTOPIC FOR CHILDREN < 2 YEARS. QUANTITY LIMIT = 30 GM / FILL, 90 GM / 6 MOS. STEP THERAPY REQUIRED (PREVIOUS TRIAL OF TOPICAL STEROID FOR PATIENTS ≥ 2 YRS). PROTOPIC OINTMENT CONCENTRATION LIMITED TO 0.03% FOR AGE < 16 YEARS OLD.

NO PA REQUIRED

ELIDEL® (pimecrolimus) §
PROTOPIC® (tacrolimus) §

PA REQUIRED

Elidel® (age < 2 yrs)
Protopic® (age < 2 yrs)

LIPOTROPICS: BILE ACID SEQUESTRANTS

LENGTH OF AUTHORIZATION: LIFETIME

NO PA REQUIRED

CHOLESTYRAMINE† powder (compare to Questran®)
CHOLESTYRAMINE LIGHT† powder (compare to Questran Light®)
PREVALITE† powder (cholestyramine light)

COLESTIPIOL† tablets, granules (compare to Colestid®)

PA REQUIRED

Questran®* powder (cholestyramine)
Questran Light®* powder (cholestyramine light)

Colestid®* tablets, granules (colestipol)
Welchol® (colesevelam)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

LIPOTROPICS: FIBRIC ACID DERIVATIVES

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

GEMFIBROZIL® † (compare to Lopid®)
♦TRICOR® (fenofibrate) §

♦PA required if patient not on concurrent statin

PA REQUIRED

Antara® (fenofibrate micronized) §
fenofibrate† §
fenofibrate micronized† §
Lipofen® (fenofibrate) §
Lofibra® (fenofibrate micronized) Capsules §
Lofibra® (fenofibrate) Tablets §
Lopid®* (gemfibrozil) §
Triglide® (fenofibrate) §

LIPOTROPICS: NIACIN DERIVATIVES

LENGTH OF AUTHORIZATION: N/A

NO PA REQUIRED

NIACIN†
NIASPAN® (niacin)
NIASPAN® ER (niacin)

PA REQUIRED

LIPOTROPICS: STATINS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

NO PA REQUIRED

LOVASTATIN† (compare to Mevacor®) (QL = 1 tablet/day (10 & 20 mg), 2 tabs/day (40 mg))
PRAVASTATIN† (compare to Pravachol®) (QL = 1 tablet/day (10 & 20 mg), 2 tabs/day (40 mg))

PA REQUIRED

Low/Medium Potency Statins

Altoprev® (aka: Altocor®) (lovastatin) (QL = 1 tablet/day)
Lescol® (fluvastatin) (QL = 1 tablet/day)
Lescol® XL (fluvastatin XL) (QL = 1 tablet/day)
Mevacor®* (lovastatin) (QL = 1 tab/day (10 & 20 mg), 2 tabs/day (40 mg))
Pravachol®* (pravastatin) (QL = 1 tab/day (10 & 20 mg), 2 tabs/day (40 mg))
Pravastatin † 80 mg Tablet (use 40 mg tablets)

High Potency Statins

SIMVASTATIN† (compare to Zocor) (QL = 1 tablet/day)
CRESTOR® (rosuvastatin calcium) §
AFTER GENERIC SIMVASTATIN TRIAL
(QL = 1 tablet/day)

Lipitor® (atorvastatin) (QL = 1 tablet/day)
Zocor®* (simvastatin) (QL = 1 tablet/day)

LIPOTROPICS: MISCELLANEOUS/COMBINATIONS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

NO PA REQUIRED

ZETIA® (ezetimibe) § (AFTER CLINICAL CRITERIA ARE MET)
(Qty Limit = 1 tablet/day)

PA REQUIRED

Miscellaneous

Lovaza® (omega-3-acid ethyl esters)

Cholesterol Absorption Inhibitors/Combinations

Vytorin® (ezetimibe/simvastatin) (QL = 1 tablet/day)

Other Statin Combinations

ADVICOR® (lovastatin/niacin)

Caduet® (atorvastatin/amlodipine)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

MISCELLANEOUS: ELAPRASE® (HUNTER'S SYNDROME INJECTABLE)**LENGTH OF AUTHORIZATION: 1 YEAR****QUANTITY LIMITS APPLY****NO PA REQUIRED****PA REQUIRED**Elaprase® (idursulfase) (*QL = calculated dose/week*)**MISCELLANEOUS: SOLIRIS® (PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INJECTABLE)****LENGTH OF AUTHORIZATION: INITIAL 3 MONTHS, SUBSEQUENT 1 YEAR****QUANTITY LIMITS APPLY****NO PA REQUIRED****PA REQUIRED**Soliris® (eculizumab) (*Quantity Limit = 20 vials total/3 months initially; 6 vials/month subsequently*)**MOOD STABILIZERS (SEE ALSO ANTICONVULSANTS)****LENGTH OF AUTHORIZATION: DURATION OF NEED****NO PA REQUIRED****PA REQUIRED**

EQUETRO® (carbamazepine)

LITHIUM CARBONATE† (compare to Eskalith®)

LITHIUM CARBONATE SR† (compare to Eskalith CR®, Lithobid®)

LITHIUM CITRATE SYRUP†

MULTIPLE SCLEROSIS: INJECTABLES**LENGTH OF AUTHORIZATION: 5 YEARS****QUANTITY LIMITS APPLY****NO PA REQUIRED****PA REQUIRED****Interferons**

BETASERON® (interferon B-1b)

COPAXONE® (glatiramer acetate) (*QL = 1 kit/30 days*)

REBIF® (interferon B-1a)

Other

AVONEX® (interferon B-1a)

NUTRITIONALS, ENTERAL**LENGTH OF AUTHORIZATION: 6 MONTHS****THERAPY SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.****NO PA REQUIRED****PA REQUIRED**PA applies to oral (swallowed) liquid nutrition: Contact MedMetrics.
For enteral nutrition requiring DME equipment and supplies call OVHA
Clinical staff for authorization.**OPHTHALMICS: ANTIHISTAMINES****LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED****PA REQUIRED**

ELESTAT® (epinastine)

PATANOL® (olopatadine)

Emadine® (emedastine)

ketotifen†

Optivar® (azelastine)

Zaditor® (ketotifen)

PDL KEY:**† GENERIC PRODUCT***** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA****§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

OPHTHALMICS: GLAUCOMA AGENTS/MIOTICS

LENGTH OF AUTHORIZATION: LIFETIME

NO PA REQUIRED

ALPHA-2 ADRENERGIC

ALPHAGAN® P (brimonidine tartrate)
BRIMONIDINE TARTARATE† (compare to Alphagan®)

BETA BLOCKER

BETAXOLOL HCl† (compare to Betoptic®)
BETOPTIC S® (betaxolol suspension)
CARTEOLOL HCl† (compare to Ocupress®)
LEVOBUNOLOL HCl† (compare to AKBeta®, Betagan®)
METIPRANOLOL†(compare to Optipranolol®)
TIMOLOL MALEATE† (compare to Istalol®, Timoptic®)

PROSTAGLANDIN INHIBITORS

Note: Coverage of a 'preferred' PI agent is contingent upon a 1st-line trial of any other preferred beta-blocker, a-2 adrenergic or CAI agent. Coverage of a 'non-preferred' PI agent is contingent upon a similar first-line trial as well as a failed trial of both preferred PI products.

LUMIGAN® (bimatoprost) §
TRAVATAN®/TRAVATAN Z® (travoprost) §

CARBONIC ANHYDRASE INHIBITOR

COSOPT® (dorzolamide w/timolol)
TRUSOPT® (dorzolamide)

MISCELLANEOUS

DIPIVEFRIN HCl† (compare to AKPro®, Propine®)
EPINEPHRINE† (compare to Epifrin®, Glaucon®*)
ISOPTO® CARBACHOL (carbachol)
ISOPTO® CARPINE (pilocarpine)
PILOCARPINE HCl† (compare to Pilocar®)
PILOPINE® (pilocarpine)
PHOSPHOLINE IODIDE® (echothiophate)

PA REQUIRED

Iopidine® (apraclonidine) - no PA required for pts <=10yrs

Betagan®*
Betimol®*
Istalol®*
Optipranolol®*
Timoptic®*
Timoptic XE®*

Xalatan® (latanoprost)

Azopt® (brinzolamide)

Miochol-E®
Miostat®
Pilocar®*
Propine®*

OPHTHALMICS: MAST CELL STABILIZERS

LENGTH OF AUTHORIZATION: 6 MONTHS

NO PA REQUIRED

ALAMAST® (pemirolast potassium)
CROMOLYN SODIUM† (compare to Crolom®, Opticrom®)

PA REQUIRED

Alocril® (nedocromil sodium)
Alomide® (iodoxamide)
Crolom®*

OPHTHALMICS: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

ACULAR® (ketorolac 0.5% ophthalmic sol.)
ACULAR LS ® (ketorolac 0.4% ophthalmic sol.)
ACULAR® PF (ketorolac 0.5% ophthalmic sol.)
FLURBIPROFEN 0.03% ophthalmic sol. †

PA REQUIRED

Nevanac® ophthalmic susp. (nepafenac 0.1%)
Xibrom® ophthalmic sol. (bromfenac 0.09%)
Ocufer®* ophthalmic sol. (flurbiprofen 0.03%)
Voltaren® (diclofenac 0.1% ophthalmic sol.)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

OPHTHALMICS: QUINOLONE ANTI-INFECTIVES**LENGTH OF AUTHORIZATION: FOR DATE OF SERVICE, NO REFILLS****NO PA REQUIRED**

CIPROFLOXACIN HCl† (compare to Ciloxan®)
OFLOXACIN† (compare to Ocuflax®)

PA REQUIRED

Ciloxan®*
Ocuflax®*
Quixin® (levofloxacin)
Vigamox® (moxifloxacin)
Zymar® (gatifloxacin)

OSSIFICATION ENHANCERS**LENGTH OF AUTHORIZATION: LIFETIME****QUANTITY LIMITS APPLY****NO PA REQUIRED****ORAL BISPHOSPHONATES**

BONIVA® (ibandronate) 150 mg (*Quantity Limit = 1 tab/28 days*)
BONIVA® (ibandronate) 2.5 mg *No quantity limits*
FOSAMAX® (alendronate)
FOSAMAX PLUS D® (alendronate/vitamin D)

PA REQUIRED

Actonel® (risedronate)
Actonel® w/calcium (risedronate/calcium)
Didronel® (etidronate)
Etidronate (compare to Didronel®)
Skelid® (tiludronate)

INJECTABLE BISPHOSPHONATES

MIACALCIN® (calcitonin)

Boniva® Injection (ibandronate) (*Quantity Limit = 3 mg/3 months (four doses)/year*)
Reclast® Injection (zoledronic acid) (*Quantity Limit = 5 mg (one dose)/year*)
Fortical® (calcitonin)
Forteo® (teriparatide) (*Quantity Limit = 1 pen (3 ml)/28 days*)

OTIC: ANTI-INFECTIVES**LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**

CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%; otic susp.)
FLOXIN® (ofloxacin 0.3%; otic soln.)
NEOMYCIN/POLYMYXIN B SULFATE/HYDROCORTISONE †

PA REQUIRED

Cipro-HC® (ciprofloxacin 0.2%/hydrocortisone 1%; otic susp.)
Ofloxacin† 0.3 % otic solution
Coly-Mycin S®/Cortisporin TC®
(neomycin/colistin/thonzium/hydrocortisone)
Cortisporin otic®/Pediotic®* (neomycin/polymyxin B sulfate /hydrocortisone)
otic solution/sus

PDL KEY:**† GENERIC PRODUCT***** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA****§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

PARKINSON'S: NON-ERGOT DOPAMINE RECEPTOR AGONIST

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

NO PA REQUIRED

DOPAMINE PRECURSOR

CARBIDOPA/LEVODOPA† (compare to Sinemet®)
CARBIDOPA/LEVODOPA† ER (compare to Sinemet® CR)
PARCOPA® (carbidopa/levodopa ODT)

DOPAMINE AGONISTS

BROMOCRIPTINE† (compare to Parlodel®)
MIRAPEX® (pramipexole)
REQUIP® (ropinirole)

COMT INHIBITORS

TASMAR® (tolcapone)
COMTAN® (entacapone)

MAO-B INHIBITORS

SELEGILINE† (compare to Eldepryl®)

PA REQUIRED

Sinemet®*
Sinemet CR®*

Parlodel® (bromocriptine)

OTHER

AMANTADINE† (compare to Symmetrel®)
STALEVO® (carbidopa/levodopa/entacapone)

Eldepryl® (selegiline)
Azilect® (rasagiline) (QL = 1 mg/day)
Zelapar® (selegiline ODT) (QL = 2.5 mg/day)

Symmetrel® (amantadine)

PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS

LENGTH OF AUTHORIZATION: 1 YEAR

QUANTITY LIMITS APPLY

EFFECTIVE 7/1/06, PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS ARE NO LONGER A COVERED BENEFIT FOR ALL VERNONT PHARMACY PROGRAMS FOR THE TREATMENT OF ERECTILE DYSFUNCTION. THIS CHANGE IS RESULTANT FROM CHANGES SET INTO EFFECT JANUARY 1, 2006 AND AS DETAILED IN SECTION 1903 (I)(21)(K) OF THE SOCIAL SECURITY ACT (THE ACT), PRECLUDING MEDICAID FEDERAL FUNDING FOR OUTPATIENT DRUGS USED FOR THE TREATMENT OF SEXUAL OR ERECTILE DYSFUNCTION. SILDENAFIL WILL REMAIN AVAILABLE FOR COVERAGE VIA PRIOR-AUTHORIZATION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.

PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET

Revatio® (sildenafil) (Quantity Limit = 3 tabs/day)
Viagra® (sildenafil) (Quantity Limit = 3 tabs/day)

PLATELET INHIBITORS

LENGTH OF AUTHORIZATION: 3 YEARS

NO PA REQUIRED

AGGREGATION INHIBITORS

CILOSTAZOL† (compare to Pletal®)
CLOPIDOGREL† (compare to Plavix®)
PLAVIX® (clopidogrel bisulfate)
TICLOPIDINE† (compare to Ticlid®)

PA REQUIRED

Pletal®*
Ticlid®*

OTHER

ASPIRIN†
DIPYRIDAMOLE† (compare to Persantine®)

Aggrenox® (dipyridamole/ASA)
Persantine®*

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

PSORIASIS INJECTABLES**LENGTH OF AUTHORIZATION: INITIAL PA OF 3 MONTHS, 12 MONTHS THEREAFTER.****QUANTITY LIMITS APPLY****THERAPY-SPECIFIC PA FAX FORM AVAILABLE ON OVHA WEBSITE.****PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**ENBREL® (etanercept)
RAPTIVA® (efalizumab)**NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**Amevive® (alefacept)
Remicade® (infliximab)**PSORIASIS: NON-BIologICS****LENGTH OF AUTHORIZATION: 1 YEAR****QUANTITY LIMITS APPLY****NO PA REQUIRED**CYCLOSPORINE † (all brand and generic)
METHOTREXATE † (all brand and generic)
OXSORALEN-ULTRA® (methoxsalen)
SORIATANE® CK (acitretin)**PA REQUIRED****Oral**DOVONEX® (calcipotriene cream)
PSORIATEC®, DRITHO-SCALP® (anthralin cream)
TAZORAC® (tazarotene cream, gel)**Topical**Taclonex® (calcipotriene/betamethasone ointment)
(QL for initial fill = 60 grams)**PULMONARY: ANTICHOLINERGICS, INHALED****LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED****METERED DOSE INHALER (SINGLE AGENT)**
ATROVENT HFA® (ipratropium)
SPIRIVA® (tiotropium)**PA REQUIRED****NEBULIZER (SINGLE AGENT)**
IPRATROPIUM SOLN FOR INHALATION**METERED DOSE INHALER (COMBINATION PRODUCT)**
COMBIVENT® (ipratropium/albuterol)**NEBULIZER (COMBINATION PRODUCT)**
DUONEB® (ipratropium/albuterol)

Ipratropium/albuterol† (compare to Duoneb®)

PULMONARY: ANTIHISTAMINES-1ST GENERATION**LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**All generic antihistamines

All generic antihistamine/decongestant combinations**PA REQUIRED**All brand antihistamines (example: Benadryl®)

All brand antihistamine/decongestant combinations (example: Deconamine SR®, Rynatan®, Ryna-12®)**PDL KEY:****† GENERIC PRODUCT***** INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA****§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

PULMONARY: ANTIHISTAMINES-2ND GENERATION**LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**

LORATADINE (OTC) †

FEXOFENADINE § (after 15-day loratadine trial and failure w/in last 30 days)

LORATADINE/D (OTC) †

LORATADINE (OTC) † syrup
ZYRTEC® (cetirizine) SYRUP (age <12 yrs)

LORATADINE (OTC) † chewable tablets

PA REQUIREDAllegra® (fexofenadine) §
Clarinex® (desloratadine) §
Claritin® §
Zyrtec® (cetirizine) §Allegra-D® § (12 HR & 24 HR)
Clarinex-D® § (12 HR & 24 HR)
Claritin-D® §
Zyrtec-D® §Allegra® suspension §
Clarinex® Syrup §
Claritin Syrup®*§
Zyrtec Syrup® (age ≥ 12 yrs) §Clarinex RediTabs® §
Claritin RediTabs®*§
Zyrtec® Chewable Tablets §**PULMONARY: PERSISTENT ASTHMA****LENGTH OF AUTHORIZATION: 3 MONTHS AFTER CLINICAL CRITERIA ARE MET.****THERAPY SPECIFIC CLINICAL CRITERIA ARE AVAILABLE ON THE OVHA WEBSITE.****NO PA REQUIRED****PA REQUIRED**

Xolair® (omalizumab)

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

PULMONARY: BETA-ADRENERGIC AGENTS

LENGTH OF AUTHORIZATION: 5 YEARS

EFFECTIVE 11/1/06: ALBUTEROL SULFATE MDI MOVES TO "PA REQUIRED" (EXISTING USERS OF THIS PRODUCT WILL MAINTAIN COVERAGE WITHOUT PRIOR AUTHORIZATION INDEFINITELY VIA GRANDFATHERING PROVISIONS)

NO PA REQUIRED

METERED-DOSE INHALERS (SHORT-ACTING)

XOPENEX® HFA (levalbuterol)

PA REQUIRED

- albuterol MDI†
Alupent® (metaproterenol)
Maxair® Autohaler (pirbuterol)
• Proair® (albuterol)
• Proventil® HFA (albuterol)
• Ventolin® HFA (albuterol)

• coverage grandfathered for current users

METERED-DOSE INHALERS (LONG-ACTING)

FORADIL® (formoterol) (*after criteria for LABA are met*)
SEREVENT® DISKUS (salmeterol xinafoate) (*after criteria for LABA are met*)

NEBULIZER SOLUTIONS (SHORT-ACTING)

ACCUNEB® (albuterol sulfate solution 0.63 mg/ml and 1.25 mg/ml)
ALBUTEROL 0.83 mg/ml neb solution †
METAPROTERENOL† neb solution
XOPENEX® neb solution (levalbuterol HCL) (age ≤ 12 yrs)

albuterol sulfate solution † 0.63 mg/ml and 1.25 mg/ml (compare to Accuneb®)
Xopenex® neb solution (age > 12 yrs)

NEBULIZER SOLUTIONS (LONG-ACTING)

Brovana® (arformoterol) *QL = 2 vial/day*

TABLETS/SYRUP (SHORT-ACTING)

TERBUTALINE† tablets (compare to Brethine®)
ALBUTEROL † tablets/syrup
METAPROTERENOL †tablets/syrup

Brethine®* (terbutaline)

TABLETS (LONG-ACTING)

ALBUTEROL ER † tablets

Vospire ER®* (albuterol)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

PULMONARY: INHALED GLUCOCORTICOIDS/GLUCOCORTICOID COMBINATIONS

LENGTH OF AUTHORIZATION: 5 YEARS

NO PA REQUIRED

METERED DOSE INHALERS (SINGLE AGENT)

ASMANEX® (mometasone furoate) ((QL = 0.72 gm (3 inhalers)/90 days))
AZMACORT® (triamcinolone acetonide)
FLOVENT® DISKUS (fluticasone propionate)
FLOVENT® HFA (fluticasone propionate) (QL = 36 gm(3 inhalers)/90 days)
PULMICORT Flexhaler® (budesonide)

METERED DOSE INHALERS (COMBINATION PRODUCT)

ADVAIR® DISKUS (fluticasone/salmeterol)
ADVAIR® HFA (fluticasone/salmeterol)
SYMBICORT® (budesonide/formoterol) (QL = 30.6 gm (3 inhalers)/90 days)

NEBULIZER SOLUTIONS

PULMICORT RESPULES® (budesonide) (age ≤ 12 yrs)

PA REQUIRED

AeroBid® (flunisolide) §
AeroBid-M® §
QVAR® (beclomethasone) §

Pulmicort (budesonide) Respules® (age > 12 yrs)

PULMONARY: NASAL GLUCOCORTICOIDS

LENGTH OF AUTHORIZATION: 5 YEARS

NO PA REQUIRED

FLUTICASONE Propionate † (compare to Flonase®)
FLUNISOLIDE† 25 mcg/spray (previously Nasalide®)
NASACORT AQ® (triamcinolone AQ)
NASONEX® (mometasone)

PA REQUIRED

Beconase AQ® (beclomethasone AQ)
Flonase®* (fluticasone propionate)
flunisolide† 29 mcg/spray (compare to Nasarel®)
Nasarel® (flunisolide)
Rhinocort AQ® (budesonide AQ)
Veramyst® (fluticasone furoate)

PULMONARY: SYSTEMIC GLUCOCORTICOIDS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

CORTISONE ACETATE†
DEXAMETHASONE†
HYDROCORTISONE† (compare to Cortef®)
METHYLPREDNISOLONE† (compare to Medrol®)
ORAPRED® oral solution/ODT (prednisolone sod phosphate) (age < 12 yrs)
PREDNISOLONE† tabs / liquid (compare to Pediapred®, Prelone®)
PREDNISONE†

PA REQUIRED

Celestone®
Cortef®*
Medrol®*
Orapred® oral solution (age ≥ 12 yrs)
Orapred® ODT (age ≥ 12 yrs)
Pediapred®*
Prelone®*

PULMONARY: LEUKOTRIENE MODIFIERS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

ACCOLATE® (zafirlukast)
SINGULAIR® (montelukast sodium)

PA REQUIRED

ZyFlo® (zileuton) §
ZyFlo® CR (zileuton SR) §

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

PULMONARY: RSV PREVENTION**LENGTH OF AUTHORIZATION: 1 SEASON, 6 DOSES (NOVEMBER 1-APRIL 30)****QUANTITY LIMITS APPLY****NO PA REQUIRED****PA REQUIRED:** Therapy specific PA fax form is available on the OVHA website

SYNAGIS® (palivizumab)

RENAL DISEASE: PHOSPHATE BINDERS**LENGTH OF AUTHORIZATION: N/A****NO PA REQUIRED**FOSRENOL® (lanthanum carbonate)
PHOS LO® (calcium acetate)
RENAGEL® (sevelamer)**PA REQUIRED****RHEUMATOID & PSORIATIC ARTHRITIS: IMMUNOMODULATORS****LENGTH OF AUTHORIZATION: INITIAL PA OF 3 MONTHS; 12 MONTHS THEREAFTER****QUANTITY LIMITS APPLY****THERAPY SPECIFIC PA FAX FORM IS AVAILABLE ON THE OVHA WEBSITE.****PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**ENBREL® (etanercept)
HUMIRA® (adalimumab)**NON-PREFERRED AGENTS AFTER CLINICAL CRITERIA ARE MET**Kineret® (anakinra)
Orencia® (abatacept)
Remicade® (infliximab)**SALIVA STIMULANTS****LENGTH OF AUTHORIZATION: 1 YEAR****NO PA REQUIRED**PILOCARPINE (compare to Salagen®)
EVOXAC® (cevimeline)**PA REQUIRED**

Salagen®* (pilocarpine)

SEDATIVE/HYPNOTICS**LENGTH OF AUTHORIZATION: 1 YEAR****QUANTITY LIMITS APPLY****NO PA REQUIRED**CHLORAL HYDRATE† syrup, suppository
ESTAZOLAM† (compare to Prosom®)
FLURAZEPAM† (compare to Dalmane®)
TEMAZEPAM† (compare to Restoril®)**PA REQUIRED****Benzodiazepine**Dalmane®*
Doral® (quazepam)
Prosom®*
Restoril®*
Somnot®
triazolam† and Halcion®**Non-benzodiazepine**LUNESTA® (eszopiclone) (*Quantity Limit = 1 tab/day*)
ZOLPIDEM † (compare to Ambien®) (*Quantity Limit = 1 tab/day*)Ambien®* (zolpidem) (*Quantity Limit = 1 tab/day*)
Ambien CR® (zolpidem) (*Quantity Limit = 1 tab/day*)
Rozerem® (ramelteon) (*Quantity Limit = 1 tab/day*)
Sonata® (zaleplon)**PDL KEY:**† **GENERIC PRODUCT*** **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**

SKELETAL MUSCLE RELAXANTS

LENGTH OF AUTHORIZATION: 1 YEAR

EFFECTIVE 11/1/06: ALL CARISOPRODOL PRODUCTS (BRAND AND GENERICS) MOVE TO "PA REQUIRED"

NO PA REQUIRED

CHLORZOXAZONE† (compare to Parafon Forte DSC®)
CYCLOBENZAPRINE† (compare to Flexeril®)
METHOCARBAMOL† (compare to Robaxin®)
METHOCARBAMOL, ASA† (compare to Robaxisal®)
ORPHENADRINE CITRATE† (compare to Norflex®)
ORPHENADRINE, ASA, CAFFEINE† (compare to Norgesic®, Norgesic Forte®)

ASA = aspirin

PA REQUIRED

Musculoskeletal Agents

Amrix® (cyclobenzaprine extended release)
carisoprodol †
carisoprodol, ASA†
carisoprodol, ASA, codeine †
Fexmid® (cyclobenzaprine)
Flexeril®*
Norflex®*
Norgesic®*
Norgesic Forte®*
Parafon Forte DSC®*
Robaxin®*
Robaxisal®*
Skelaxin®
Soma®
Soma Compound®
Soma Compound with Codeine®

Antispasticity Agents

BACLOFEN† (compare to Lioresal®)
DANTROLENE† (compare to Dantrium®)
TIZANIDINE† (compare to Zanaflex®)

Dantrium®*
Lioresal®*
Zanaflex®*

SMOKING CESSATION THERAPIES

LENGTH OF AUTHORIZATION: SEE TABLE

QUANTITY LIMITS APPLY

NO PA REQUIRED

NICOTINE REPLACEMENT (maximum duration is 16 weeks (2 x 8 weeks)/365 days)▲

NICODERM CQ PATCH®
NICORETTE GUM®
COMMIT LOZENGE®
NICOTINE LOZENGE†
NICOTROL INHALER®

nicotine patch OTC†
nicotine patch RX† (compare to Habitrol®)
Nicotine System Kit®
nicotine gum†
Nicotrol Nasal Spray®

ORAL THERAPY

BUPROPION SR†
CHANTIX® (varenicline) (Limited to 18 years and older, Quantity Limit = 2 tabs/day, maximum duration 24 weeks (2 x 12 weeks)/365 days)▲

Zyban®* (bupropion SR)
(maximum duration 24 weeks (2 x 12 weeks)/365 days)

▲ For approval of therapy beyond the established maximum duration, the prescriber must provide evidence that the patient is engaged in a smoking cessation counseling program.

PDL KEY:

† GENERIC PRODUCT

* INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA

§ INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)

URINARY ANTISPASMODICS

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED*

SHORT-ACTING AGENTS

OXYBUTYNIN† (compare to Ditropan®)

LONG-ACTING AGENTS

ENABLEX® (darifenacina)

OXYBUTYNIN XL† (compare to Ditropan® XL)

SANCTURA® (trospium)

VESICARE® (solifenacina)

PA REQUIRED

Ditropan®*

Flavoxate † (compare to Urispas®)

Urispas® (flavoxate)

Detrol® (tolterodine)

Detrol LA® (tolterodine LA)

Ditropan XL® (oxybutynin XL)

Oxytrol® (oxybutynin transdermal)

>NOTE:

- Patients under the age of 65 must fail an adequate trial of generic oxybutynin before approval will be granted for either oxybutynin XL®, Vesicare®, Sanctura® or Enablex®.
- A therapeutic failure on at least two long acting preferred products is required before a PA will be approved on any non-preferred long acting medication.

Recipients < 21 years of age are exempt from all PA Requirements.

(Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan®/Ditropan® XL will be granted)

VAGINAL ANTI-INFECTIVES

LENGTH OF AUTHORIZATION: 1 YEAR

NO PA REQUIRED

CLINDAMYCIN

CLINDAMYCIN VAGINAL† (clindamycin vaginal cream 2%)

CLINDAMAX† (clindamycin vaginal cream 2%)

METRONIDAZOLE

METRONIDAZOLE VAGINAL GEL 0.75%†

VANDAZOLE† (metronidazole vaginal 0.75%)

PA REQUIRED

Cleocin®* (clindamycin vaginal cream 2%)

Clindesse® (clindamycin vaginal cream 2%)

Cleocin® Vaginal Ovules (clindamycin vaginal suppositories)

Metrogel Vaginal®* (metronidazole vaginal gel 0.75%)

PDL KEY:

† **GENERIC PRODUCT**

* **INDICATES A GENERIC EQUIVALENT IS AVAILABLE WITHOUT PA**

§ **INDICATES DRUG IS MANAGED VIA AUTOMATED STEP THERAPY (PREREQUISITE DRUG THERAPY AUTOMATICALLY SCREENED FOR UPON CLAIMS PROCESSING)**